Neurology

Results suggest that a single, brief exposure to general anesthesia for surgery is unlikely to impair short-term neurodevelopment in young children.

If approved, vatiquinone would have been the first therapy approved for pediatric patients with FA.

Additionally, long sleep duration could be associated with increased odds of being reliably symptomatic at 4 weeks.

The patient described the headache as “pressure-like,” episodes that occurred for 1 to 2 hours with high severity.

Currently, omaveloxolone (Skyclarys) is approved to treat adults and adolescents aged 16 years and older impacted by FA.

In this article, we recap our top stories, expert interviews, and Q+A discussions from the 2025 Pediatric Academic Societies meeting.

New data from national survey highlights disparities and need for focused prevention strategies.

In addition, data presented at PAS revealed a predictable pharmacokinetic profile in the newborn population, consistent with adult humans.

Diazepam nasal spray (Valtoco) is approved for short-term treatment of seizure clusters, now in patients aged 2 years and older.

In the immediate skin-to-skin contact group, improved breastfeeding practices up to 12 months were observed.

Infants born moderately preterm had lower composite cognitive scores compared to those born at full-term s (β = −0.39; 95% CI, −0.55 to −0.22; P < .001).

If approved, the expanded indication would include children and adolescents aged 6 to 17 years who weigh 99 lbs (45 kg) or more.

Submission is based on 3 clinical trials, including data from the ApproaCH Trial among children with achondroplasia.

Diazoxide choline has been granted breakthrough, fast track, and orphan drug designations in the United States.

The PANDAS/PANS questionnaire is based on symptoms and comorbidities described in the literature and is a self-report completed by parents of children younger than 18.

Results were from the phase 3 STEER study among a broad population of patients with SMA aged 2 to under 18 years.

First approved for PNH in 2007, the monoclonal antibody is now the first and only treatment for pediatric patients living with gMG.

The FDA has accepted PTC Therapeutics' NDA for vatiquinone, a potential treatment for Friedreich's ataxia, with a decision expected by August 19, 2025.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The new risdiplam tablet is suitable for those aged 2 years and older who weigh more than 44 lbs, according to Genentech.

Cyclo Therapeutics has enrolled 10 patients in a single-arm sub-study treating newborns to 3 years of age, evaluating the Trappsol Cyclo in the youngest subsets.

A recap of the FDA submissions and regulatory decisions in pediatrics from January 2025.

Application submission is based on positive phase 3 data that demonstrated improvement in patients with type 2 and 3 SMA receiving current standard of care.

The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months.

"In aggregation with other robust observational studies, these results can inform the management of asthma and allergic rhinitis in this patient group," wrote the study authors.